Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis

ABSTRACT Background Obesity represents a major global health challenge, contributing substantially to cardiovascular disease and metabolic complications. Orforglipron, a novel oral non‐peptide GLP‐1 receptor agonist, has emerged as a promising therapeutic option for weight management and glycemic co...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ravi Kumar Pandey, Mahnoor Jan, Aqsa Mohammad, Khawaja Arham Jawaid, Mawra Naveed, Muhammad Ali Abid, Abdullah Bin Amir, Shafique Ahmed, Muhammad Safiullah, Muhammad Imaz Bhatti, Sana Iftikhar, Muhammad Nabeel Saddique, Widyan Alfalh, Rihab Mohammed bin Omar, Husam Abu Dawood
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2025-11-01
Ráidu:	Endocrinology, Diabetes & Metabolism
Fáttát:	GLP‐1 receptor agonist glycemic control meta‐analysis obesity orforglipron type 2 diabetes mellitus
Liŋkkat:	https://doi.org/10.1002/edm2.70134
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!